ENSC Insider Trading

Insider Ownership Percentage: 52.70%
Insider Buying (Last 12 Months): $44,240.63
Insider Selling (Last 12 Months): $0.00

Ensysce Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Ensysce Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ensysce Biosciences Share Price & Price History

Current Price: $4.86
Price Change: Price Decrease of -1.93 (-28.42%)
As of 03/31/2023 01:00 AM ET

This chart shows the closing price history over time for ENSC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Ensysce Biosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/2/2023Bob G GowerDirectorBuy90,287$0.49$44,240.631,222,682View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Ensysce Biosciences (NASDAQ:ENSC)

Ensysce Biosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/14/2023Two Sigma Investments LP39,870$30K0.0%N/A0.348%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Ensysce Biosciences logo
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Read More on Ensysce Biosciences

Today's Range

Now: $4.86
Low: $4.68
High: $6.13

50 Day Range

MA: $0.61
Low: $0.48
High: $0.80

52 Week Range

Now: $4.86
Low: $4.68
High: $396.00


188,025 shs

Average Volume

198,946 shs

Market Capitalization

$73.05 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Ensysce Biosciences?

Ensysce Biosciences' top insider shareholders include:
  1. Bob G Gower (Director)
Learn More about top insider investors at Ensysce Biosciences.

Who are the major institutional investors of Ensysce Biosciences?

Ensysce Biosciences' top institutional shareholders include:
  1. Two Sigma Investments LP — 0.35%
  2. Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of Ensysce Biosciences stock.

Which major investors are buying Ensysce Biosciences stock?

During the last quarter, ENSC stock was bought by institutional investors including:
  1. Two Sigma Investments LP